Loading
HKSEHealthcareBiotechnology
Latest quote
HK$2.36
+HK$0.095 · +4.19%
Established in 2014 and headquartered in Qingdao, China, 3D Medicines Inc. is a biopharmaceutical company dedicated to the discovery, development, and market introduction of innovative oncology drugs and therapeutic candidates. Its core mission is to address diverse cancer types, primarily serving patients in Mainland China. The company's flagship product, Envafolimab, is a PD-L1 antibody administered via subcutaneous injection. This treatment is approved for advanced solid tumors characterized by microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status in patients who have undergone previous therapies. Beyond its currently marketed drug, 3D Medicines boasts a robust development pipeline. Two significant candidates are currently undergoing Phase III clinical trials: 3D189, which targets multiple tumor indications, and 3D229 (a GAS6/AXL inhibitor), under investigation for non-small cell lung cancer, ovarian cancer, and kidney cancer. The company's Phase II pipeline includes 3D1001, designed to manage postoperative dental pain and tumor-related discomfort, and 3D1002, also aimed at oncology pain relief. Additionally, 3D185 is in Phase I clinical evaluation for locally advanced or metastatic solid tumors. Further promising candidates in earlier stages encompass 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumors, and 3D057 for various types of tumors.
Latest quote
HK$2.36
+HK$0.095 · +4.19%
Regular session · HKT · Market data may be delayed.
Established in 2014 and headquartered in Qingdao, China, 3D Medicines Inc. is a biopharmaceutical company dedicated to the discovery, development, and market introduction of innovative oncology drugs and therapeutic candidates. Its core mission is to address diverse cancer types, primarily serving patients in Mainland China. The company's flagship product, Envafolimab, is a PD-L1 antibody administered via subcutaneous injection. This treatment is approved for advanced solid tumors characterized by microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status in patients who have undergone previous therapies. Beyond its currently marketed drug, 3D Medicines boasts a robust development pipeline. Two significant candidates are currently undergoing Phase III clinical trials: 3D189, which targets multiple tumor indications, and 3D229 (a GAS6/AXL inhibitor), under investigation for non-small cell lung cancer, ovarian cancer, and kidney cancer. The company's Phase II pipeline includes 3D1001, designed to manage postoperative dental pain and tumor-related discomfort, and 3D1002, also aimed at oncology pain relief. Additionally, 3D185 is in Phase I clinical evaluation for locally advanced or metastatic solid tumors. Further promising candidates in earlier stages encompass 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumors, and 3D057 for various types of tumors.
Day range
Current HK$2.36
52-week range
Current HK$2.36
Regular session · HKT · Market data may be delayed.
Established in 2014 and headquartered in Qingdao, China, 3D Medicines Inc. is a biopharmaceutical company dedicated to the discovery, development, and market introduction of innovative oncology drugs and therapeutic candidates. Its core mission is to address diverse cancer types, primarily serving patients in Mainland China. The company's flagship product, Envafolimab, is a PD-L1 antibody administered via subcutaneous injection. This treatment is approved for advanced solid tumors characterized by microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status in patients who have undergone previous therapies. Beyond its currently marketed drug, 3D Medicines boasts a robust development pipeline. Two significant candidates are currently undergoing Phase III clinical trials: 3D189, which targets multiple tumor indications, and 3D229 (a GAS6/AXL inhibitor), under investigation for non-small cell lung cancer, ovarian cancer, and kidney cancer. The company's Phase II pipeline includes 3D1001, designed to manage postoperative dental pain and tumor-related discomfort, and 3D1002, also aimed at oncology pain relief. Additionally, 3D185 is in Phase I clinical evaluation for locally advanced or metastatic solid tumors. Further promising candidates in earlier stages encompass 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumors, and 3D057 for various types of tumors.
Day range
Current HK$2.36
52-week range
Current HK$2.36
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 356.09M CNY | 445.65M CNY | 634.95M CNY | 567.39M CNY | 60.26M CNY |
| Cost of goods sold | 57.12M CNY | 73.91M CNY | 110.94M CNY | 42.22M CNY | 4.28M CNY |
| Gross profit | 298.97M CNY | 371.74M CNY | 524.01M CNY | 525.18M CNY | 55.98M CNY |
| Research and development | 156.1M CNY | 180.72M CNY | 425.5M CNY | 350.86M CNY | 371.16M CNY |
| Selling, general, and administrative | 255.52M CNY | 314.45M CNY | 595.89M CNY | 500.49M CNY | 193.79M CNY |
| Operating expenses | 411.62M CNY | 495.17M CNY | 1.02B CNY | 846.54M CNY | 559.07M CNY |
| Interest income | 20.33M CNY | 10.92M CNY | 6.53M CNY | 7.21M CNY | 5.5M CNY |
| Interest expense | 5.09M CNY | 9.5M CNY | 7.77M CNY | 3.11M CNY | 1.53M CNY |
| Depreciation and amortization | 8.91M CNY | 7.86M CNY | 25.46M CNY | 21.6M CNY | 12.59M CNY |
| Operating income | −112.65M CNY | −123.43M CNY | −497.25M CNY | −386.17M CNY | −516.25M CNY |
| Net income | −177.53M CNY | −182.66M CNY | −524.7M CNY | −1.02B CNY | −1.43B CNY |
Company facts updated Sep 15, 2026.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
